TOII

The Oncology Institute

TOIIW5

Penny Stock

$0.01arrow_drop_up61.47%$0.00

Penny Stock

TOII

TOIIW5

$0.01

arrow_drop_up61.47%$0.00

Penny Stock

Performance History

Key Stats
Open	$0.01
Prev. Close	$0.01
EPS	-602.08
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$0.00
PE Ratio	-

	LOW	HIGH
Day Range	0.01	0.01
52 Week Range	0.00	0.29

Ratios

Revenue	-





EPS	-602.08

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About The Oncology Institute (TOIIW)

The Oncology Institute, Inc. (TOIIW) is a company that specializes in providing oncology services and treatments to patients. With a focus on delivering high-quality care and personalized treatment plans, TOIIW aims to improve the lives of individuals facing cancer diagnoses. Their team of experienced medical professionals utilizes the latest advancements in oncology research to offer state-of-the-art treatment options.

TOIIW has a fascinating stock price history that reflects the company's growth and potential. Investors can track the performance of TOIIW stock over time to make informed decisions about buying or selling shares. By examining the historical data, investors can identify patterns and trends that may impact future stock prices.

Sector
Industry
CEO
Headquarters
Employees: 0
Exchange: NASDAQ

Keep an eye on The Oncology Institute

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is The Oncology Institute's (TOIIW) price per share?

The current price per share for The Oncology Institute (TOIIW) is $0.02. The stock has seen a price change of $0.01 recently, indicating a 61.48% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for The Oncology Institute (TOIIW)?

For The Oncology Institute (TOIIW), the 52-week high is $0.3, which is 1.41K% from the current price. The 52-week low is $0.01, the current price is 162.67% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is The Oncology Institute (TOIIW) a growth stock?

The Oncology Institute (TOIIW) has shown an average price growth of -6.03% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying The Oncology Institute as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is The Oncology Institute (TOIIW) stock price performance year to date (YTD)?

As of the latest data, The Oncology Institute (TOIIW) has a year-to-date price change of . Over the past month, the stock has experienced a price change of -1.5%. Over the last three months, the change has been 15.88%. Over the past six months, the figure is -55.53%.

help

Is The Oncology Institute (TOIIW) a profitable company?

The Oncology Institute (TOIIW) has a net income of -$83.07M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 18.37% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -16.6% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 28.42%, providing insight into the company's sales performance and growth. The gross profit is $59.57M. Operating income is noted at -$77.02M. Furthermore, the EBITDA is -$57.34M.

help

What is the market capitalization of The Oncology Institute (TOIIW)?

The Oncology Institute (TOIIW) has a market capitalization of $0. The average daily trading volume is 0.01, indicating the stock's liquidity and investor engagement.